1. Home
  2. PBYI vs PHD Comparison

PBYI vs PHD Comparison

Compare PBYI & PHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • PHD
  • Stock Information
  • Founded
  • PBYI 2010
  • PHD 2004
  • Country
  • PBYI United States
  • PHD United States
  • Employees
  • PBYI N/A
  • PHD N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • PHD Investment Managers
  • Sector
  • PBYI Health Care
  • PHD Finance
  • Exchange
  • PBYI Nasdaq
  • PHD Nasdaq
  • Market Cap
  • PBYI 126.5M
  • PHD 122.0M
  • IPO Year
  • PBYI N/A
  • PHD N/A
  • Fundamental
  • Price
  • PBYI $2.65
  • PHD $9.87
  • Analyst Decision
  • PBYI Strong Buy
  • PHD
  • Analyst Count
  • PBYI 1
  • PHD 0
  • Target Price
  • PBYI $7.00
  • PHD N/A
  • AVG Volume (30 Days)
  • PBYI 303.9K
  • PHD 67.7K
  • Earning Date
  • PBYI 10-31-2024
  • PHD 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • PHD 11.43%
  • EPS Growth
  • PBYI N/A
  • PHD N/A
  • EPS
  • PBYI 0.18
  • PHD 1.27
  • Revenue
  • PBYI $219,143,000.00
  • PHD N/A
  • Revenue This Year
  • PBYI N/A
  • PHD N/A
  • Revenue Next Year
  • PBYI N/A
  • PHD N/A
  • P/E Ratio
  • PBYI $14.56
  • PHD $7.60
  • Revenue Growth
  • PBYI N/A
  • PHD N/A
  • 52 Week Low
  • PBYI $2.13
  • PHD $8.30
  • 52 Week High
  • PBYI $7.73
  • PHD $9.81
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 52.38
  • PHD 48.43
  • Support Level
  • PBYI $2.41
  • PHD $9.82
  • Resistance Level
  • PBYI $2.69
  • PHD $9.94
  • Average True Range (ATR)
  • PBYI 0.14
  • PHD 0.06
  • MACD
  • PBYI 0.03
  • PHD -0.01
  • Stochastic Oscillator
  • PBYI 85.71
  • PHD 24.95

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About PHD Pioneer Floating Rate Fund Inc.

Pioneer Floating Rate Trust is a diversified, closed-end fund. Its investment objective is to provide a high level of current income and seek the preservation of capital by investing predominantly in floating-rate loans.

Share on Social Networks: